Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes
Date
2020Journal
JCI InsightPublisher
American Society for Clinical InvestigationType
Article
Metadata
Show full item recordAbstract
Anti-programmed cell death protein 1 (anti-PD-1) therapy has become an immunotherapeutic backbone for treating many cancer types. Although many studies have aimed to characterize the immune response to anti-PD-1 therapy in the tumor and in the peripheral blood, relatively less is known about the changes in the tumor-draining lymph nodes (TDLNs). TDLNs are primary sites of tumor antigen exposure that are critical to both regulation and cross-priming of the antitumor immune response. We used multipanel mass cytometry to obtain a high-parameter proteomic (39 total unique markers) immune profile of the TDLNs in a well-studied PD-1-responsive, immunocompetent mouse model. Based on combined hierarchal gating and unsupervised clustering analyses, we found that anti-PD-1 therapy enhances remodeling of both B and T cell compartments toward memory phenotypes. Functionally, expression of checkpoint markers was increased in conjunction with production of IFN-γ, TNF-α, or IL-2 in key cell types, including B and T cell subtypes, and rarer subsets, such as Tregs and NKT cells. A deeper profiling of the immunologic changes that occur in the TDLN milieu during effective anti-PD-1 therapy may lead to the discovery of novel biomarkers for monitoring response and provide key insights toward developing combination immunotherapeutic strategies.Sponsors
Exelixis; Bristol-Myers Squibb, BMS; American Society of Clinical Oncology, ASCO; National Institutes of Health, NIH: T32CA00971-38Keyword
anti-programmed cell death protein 1anti-PD-1 therapy
cancer
tumor
multipanel mass cytometry
Immunotherapy
Lymph Nodes
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079557938&doi=10.1172%2fjci.insight.132286&partnerID=40&md5=a2b926a59a2cbf0d18372861f645a103; http://hdl.handle.net/10713/12136ae974a485f413a2113503eed53cd6c53
10.1172/jci.insight.132286
Scopus Count
Collections
Related articles
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
- Authors: Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG
- Issue date: 2020 Nov 9
- Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
- Authors: Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE
- Issue date: 2005 Aug 1
- Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
- Authors: Bae EA, Seo H, Kim BS, Choi J, Jeon I, Shin KS, Koh CH, Song B, Kim IK, Min BS, Han YD, Shin SJ, Kang CY
- Issue date: 2018 Sep 15
- Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
- Authors: Guo Z, Wang H, Meng F, Li J, Zhang S
- Issue date: 2015 Jul 29
- The significance of cytokine-producing B cells in breast tumor-draining lymph nodes.
- Authors: Mehdipour F, Razmkhah M, Faghih Z, Bagheri M, Talei AR, Ghaderi A
- Issue date: 2019 Jun